£81.0M
The series C round was led by ORI Fund and will support clinical development of the company antibody pipeline.
H
Hepalink
OtherPortfolio
1
companies
By category
- BioTech£81.0M
By location
- Cambridge£81.0M
Portfolio
1
companies
The series C round was led by ORI Fund and will support clinical development of the company antibody pipeline.